Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis

Acta Pharmacologica Sinica

Volumn 30, Issue 3, 2009, Pages 364-371

  Ma, Ying ^b   Lin, Bi Rong ^b   Lin, Bei ^b   Hou, Sheng ^a,b   Qian, Wei Zhu ^a,b   Li, Jing ^a,b   Tan, Min ^a,b   Ma, Jian ^b   Li, Bo Hua ^a,b   Wang, Hao ^a,b   Wen, Ai Dong ^c   Guo, Ya Jun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CTLA4; ELISA; Fusion protein; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYBRID PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUSHING; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOLUNTEER; XEROSTOMIA; BLOOD; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 64849105429     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.13     Document Type: Article

References (15)

1. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEnglJMed 2005; 353: 1114-23.
2. Judith R?, Mark GL, Cynthia AG, Brian VJ, Michael TG, Bernard SG, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52.
3. Kremer JM, Westhovens R, Leon M, Eduardo DG, Rieke A, Serge S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
4. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
5. John JE, Timothy JS, James PA. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 2006; 177: 1052-61.
6. Todd DJ, Costenbader KH, Weinblatt ME. Abatacept in the treatment of rheumatoid arthritis. Int J Clin Pract 2007; 61: 494-500.
7. Grennan DM. Re: An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies, by Vaidya et al. Rheumatology (Oxford) 2002; 41: 180-3.
8. Knoerzer DB, Karr RW, Schwartz BD, Mengle LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995; 96: 987-93.
9. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-9.
10. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-71.
11. Zhou d Qian WZ, Kou G, Wang H, Liu YJ, Li XD, et al. Effect of CTLA4Ig fusion protein on human T lymphocytes. Chin Pharmacol Bull 2002; 18: 165-8.
12. Zhou Q, Kou G, Qian WZ, Wang H, Liu YJ, Wang, XY, et al. Treatment of murine allergic contact dermatitis with CTL A4-Ig. Chin J Dermatol 2002; 35: 256-9.
13. LiZG, Li J, Wen N, Tang Y, Yuan L, Wang XL, et al. Pharmaco-kinetic study of I125-CTLA4Ig: absorption, distribution and excretion after a single intravenous administration to rat. Chin J Pharm Anal 2007; 27: 949-53.
14. Nadler S, Townsend R, Mikesell, G. Abatacept (CTLA4-IG; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations. Ann Rheum Dis 2004; 63 Suppl 1: 142.
15. Wei SL, Zhang Q. Biopharmaceuticals and pharmacokinetics. 2nd ed. Beijing: Peking University Medical Press; 2004.